Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

DRUG REVIEW
[Download PDF
 
Year : 2013  |  Volume : 59  |  Issue : 3  |  Page : 208-215  

Colistin: Re-emergence of the 'forgotten' antimicrobial agent

AK Dhariwal, MS Tullu 
 Department of Pediatrics, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India

Correspondence Address:
M S Tullu
Department of Pediatrics, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra
India

Abstract

The treatment of the emerging multidrug resistant (MDR) gram-negative organisms is a challenge. The development of newer antibiotics has recently slowed down. This has led to the re-emergence of the «SQ»old forgotten«SQ» antibiotic «DQ»Colistin«DQ», whose use had almost stopped (after 1970«SQ»s) due to the high incidence of nephrotoxicity and neurotoxicity. Colistin (polymyxin E) is a polypeptide antibiotic belonging to polymyxin group of antibiotics with activity mainly against the gram-negative organisms. Use of colistin has been increasing in the recent past and newer studies have shown lesser toxicity and good efficacy. Colistin acts on the bacterial cell membrane resulting in increased cell permeability and cell lysis. Colistin can be administered orally, topically, by inhalational route, intramuscularly, intrathecally, and also intravenously. Parenteral Colistin (in the form of colistimethate sodium) has been used to treat ventilator-associated pneumonia (VAP) and bacteremia caused by MDR bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Inhaled Colistin is used for treating pneumonia/VAP due to MDR gram-negative organisms and also used prophylactically in patients with cystic fibrosis. This manuscript is a brief review of Colistin and its clinical applications in the pediatric population.



How to cite this article:
Dhariwal A K, Tullu M S. Colistin: Re-emergence of the 'forgotten' antimicrobial agent.J Postgrad Med 2013;59:208-215


How to cite this URL:
Dhariwal A K, Tullu M S. Colistin: Re-emergence of the 'forgotten' antimicrobial agent. J Postgrad Med [serial online] 2013 [cited 2020 Feb 19 ];59:208-215
Available from: http://www.jpgmonline.com/text.asp?2013/59/3/208/118040


Full Text

 Introduction



The rapid spread of multidrug-resistant (MDR) Gram-negative bacteria (GNB), such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Stenotrophomonas maltophilia, and Enterobacter (especially in intensive care units (ICUs), burn units, and immunocompromised patients) has been of concern. [1] Gram-negative Enterobacteriaceae with resistance to carbapenems (conferred by New Delhi metallo-β-lactamase 1 (NDM-1)) are an emerging problem. Kumarasamy et al., (2009), while studying the prevalence of multidrug resistant (MDR) Enterobacteriaceae found that, 75 Escherichia coli, 60 Klebsiella spp, and six other Enterobacteriaceae resistant to carbapenems were isolated from 3,521 Enterobacteriaceae isolates (Chennai). [2] Of 141 carbapenem resistant organisms, 44 were NDM-1 positive. [2] During same period, 47 from 198 isolates (24%) were identified as carbapenem-resistant from Haryana. [2] Of these, 26 (13%) were K. pneumoniae positive for NDM-1. [2] These Indian isolates were primarily from community acquired urinary tract infections, pneumonia, and blood-stream infections and most isolates were susceptible to Colistin and Tigecycline. [2]

The slow rate of development of newer antimicrobials has led to the re-discovery of the 'old' and 'forgotten' antibiotic-"Colistin", and it is increasingly being used as salvage therapy in patients with MDR GNB infections. [3] Colistin was initially discovered in Japan in 1949 and was more frequently used during the 1960s and early 1970s. [1] The use of Colistin was restricted later because of concerns regarding its neurotoxicity and nephrotoxicity; however in recent studies, Colistin has been found to be efficacious with lower toxicity. [1] The aim of this review is to discuss about the pharmacology and uses of Colistin for treatment of MDR GNB infections.

 History



Colistin belongs to polymyxin group of antibiotics, of which two (polymyxin B and E) have been used. [1] The difference between polymyxin B and Colistin lies in the amino-acid components. [1],[4] Colistin is the more commonly used because of lesser toxicity. [1] Though Colistin has been available for use in GNB infections since 1959, its use got limited when the potentially safer/less-toxic aminoglycosides and anti-pseudomonal agents became available and thus, the use of Colistin declined from 1970s to the early 2000s. [5]

 Chemical Structure



Colistin is a multi-component polypeptide antibiotic composed of Colistin A and Colistin B. [3],[4],[5] Colistin sulfate and Colistimethate sodium (CMS) are the forms of Colistin. Although CMS is the form administered parenterally, it undergoes conversion (in vivo) to form Colistin (which has antibacterial activity). [3],[4],[5],[6]

 Mechanism of Action



The antibacterial activity of Colistin is concentration-dependent (bacteriostatic in low concentrations and bactericidal in higher concentrations). [1],[4] CMS is characterized by a moderate and prolonged post-antibiotic effect (at higher concentrations) against MDR A. baumannii and P. aeruginosa strains. [1],[4] Colistin acts on the bacterial cell membrane. The cationic polypeptide (Colistin) interacts with the anionic lipopolysaccharide (LPS) molecules in the outer membrane of GNB (gram-negative bacilli) and displaces magnesium and calcium, which are the stabilizers of the LPS molecules of the outer membrane of the GNB. [1],[4] This process results in increased cell permeability, leakage of cell-contents, lysis of cell, and finally, bacterial cell death. [1],[4] Colistin also has a potent action against endotoxin-it inhibits the elaboration of cytokines and neutralizes the endotoxin. [1],[4] Hydrophilic antibiotics (rifampicin, carbapenems, glycopeptides, and tetracyclines) can work synergistically owing to the disruption of membrane integrity by Colistin. [5]

 Modes of Administration and Antibacterial Activity



Colistin can be administered orally, topically (as otic solution and skin powder as Colistin sulfate), intramuscularly, via inhalation, intrathecally, and intravenously as CMS. [4] Colistin is mostly active against Gram-negative clinical isolates including Enterobacteriaceae. [5] The non-fermentative GNB-P. aeruginosa and Acinetobacter species are naturally susceptible to Colistin. [5] Colistin is also effective against-Haemophilus influenzae, E. coli, Salmonella spp., Shigella spp., Klebsiella spp., Legionella pneumophila, Aeromonas spp., Citrobacter spp., Bordetella pertussis., and Campylobacter species (variable susceptibility). [4],[5],[7]

 Pharmacokinetics-pharmacodynamics



The pharmacokinetics (PK) of Colistin appear to be complex. [4] Most formulations contain CMS, which is hydrolyzed to various partial derivatives and Colistin in vivo. [4] Various pharmaceutical formulations often describe their contents differently, and thus, uniform and rational dosing of Colistin is challenging. [4] Both forms (Colistin sulfate and CMS) are not absorbed by the gastrointestinal (GI) tract. [1] After administration of CMS, Colistin appears rapidly in the plasma. [6] The serum half-life of this medication is 4.5-6 hours. [1] CMS is predominantly cleared by the renal route, and a fraction of the dose is converted in vivo to Colistin. [3] The Colistin formed is mainly cleared by non-renal mechanisms. In renal impairment, elimination of colistimethate (by the kidney) would be decreased and a greater fraction of colistimethate would be converted to Colistin; thus the need to decrease the dose of colistimethate in renal-impaired patients. [3] Following parenteral administration of CMS, the overall disposition of formed Colistin is rate limited by its elimination (rather than formation) as indicated by the substantially longer terminal half-life of formed Colistin (compared with that of the administered CMS). [8] The general minimum inhibitory concentration (MIC) breakpoint to identify bacteria susceptible to CMS is up to 4 mg/l based on the British Society for Antimicrobial Chemotherapy Guidelines (if MIC ≥ 8mg/l, the GNB are resistant). [1] Many authorities consider susceptibility to Colistin if the respective MIC 90 of Colistin is a maximum of 2 microg/ml (against a variety of GNB including E. coli, Klebsiella spp., Enterobacter spp., A. baumannii, and P. aeruginosa). [1] Colistin concentrations in the vicinity of MICs or above result in extremely rapid initial killing, with large decreases in colony forming units per mL (cfu/mL) occurring as early as 5 minutes following exposure. [8]

 Dosage and Formulation



There are two forms of Colistin available commercially: Colistin sulfate (tablets or syrup for oral use and powder for topical use), which is also available as an aqueous suspension solution for topical use in eyes and ears and CMS for parenteral use. [4],[7] Both these forms can be delivered by inhalation route. Colistimethate sodium is administered parenterally (less toxic than Colistin sulfate). [9] The doses of Colistin through the various routes of administration are given in [Table 1]. [4],[5],[10],[11],[12] The dosage of intravenous CMS (as recommended by the manufacturers in the USA) is 2.5-5 mg/kg (31,250-62,500 IU/kg) per day, divided into two to four equal doses. [5],[13] Dosage adjustments are recommended for patients with mild-to-moderate renal dysfunction as shown in [Table 2]. [5],[14] For patients with renal failure, the recommended intravenous dosages of CMS are 2-3 mg/kg after each hemodialysis treatment and 2 mg/kg daily during peritoneal dialysis. [5],[15],[16]{Table 1}{Table 2}

In India, parenteral colistin is available in two brands: Xylistin TM by Cipla pharmaceuticals [available as 1 million IU (International Units) and 2 million IU vials)] and Colinem TM by Macleods pharmaceuticals (available as 1 million IU per vial); the dosage being similar to that being used in United Kingdom. [17],[18] There is a substantial difference in the recommended doses of the European and US products. However, according to recent clinical experience, higher daily doses of intravenous Colistin, up-to 720 mg (9 million IU) per day, administered in large series of patients did not exhibit higher toxicity. [1],[19],[20],[21] Colistin base has been assigned a potency of 30,000 IU/mg and CMS has a potency of 12,500 IU/mg. Hence, the recommendations regarding dosing should clearly refer to Colistin base and CMS to avoid possible confusion. [5],[22]

The recommended dose of Colistin when given by inhalation is given in [Table 1]. For recurrent or severe pulmonary infections, the dose can be doubled to 160 mg (2,000,000 IU) administered every 8 hours. [10] The recommended dose for spontaneously breathing patients is 80 mg (1,000,000 IU). [10] Colistin is added to 4 ml of normal saline or sterile water and the solution is nebulized with 8 L/min oxygen flow and inhaled via a face mask. [10],[13] The optimal nebulized dosing remains unclear. Colistin is not approved by the Food and Drug Administration (FDA) to be inhaled via a nebulizer. [10]

CMS is mostly administered for 10-14 days. [5] Dose regimens vary considerably and should be adjusted for renal function depending on serum creatinine levels or creatinine clearance. [5] Colistin pharmacokinetics are different in critically ill patients as they have frequent fluctuations in renal clearance. Many authors reported the administration of CMS at a dose of 3 MIU every 8 hours, especially in critically ill patients with normal renal function. [16],[23],[24] There is inadequate data available on the safety of Colistin during pregnancy and in patients with liver function impairment. [17],[18]

 Adverse Effects



The adverse effects of Colistin are-nephrotoxicity (acute tubular necrosis in up to 20% of patients), neurotoxicity (0-7% of patients), dizziness, weakness, facial and peripheral paresthesia, vertigo, confusion, ataxia, and neuromuscular blockade (can lead to respiratory failure or apnea). [1],[5] Recent studies have reported significantly lower nephrotoxicity rates associated with Colistin administration (especially CMS). [19] The toxicity is dose-dependent and reversible on discontinuation of the treatment. [1],[5] Concomitant administration of other potential nephrotoxic agents (such as diuretics, aminoglycosides or vancomycin) increases the likelihood of nephrotoxicity. [1] Other adverse reactions include-hypersensitivity reactions, rash, urticaria, generalized itching, fever, gastro-intestinal disorders, and pseudomembranous colitis. [17],[18] The incidence of allergic reactions due to Colistin use has been reported to be about 2%. [1],[25] Bronchoconstriction and chest tightness are reported as rare complications when Colistin is used by inhalation route. [1]

 Drug Interactions



Concomitant use of Colistin with other drugs of neurotoxic and/or nephrotoxic potential (diuretics, aminoglycosides or vancomycin) should be avoided. [1] Neuromuscular blocking drugs and ether should be used with extreme caution in patients receiving CMS. [17],[18]

 Contraindications



It is contraindicated in patients with known hypersensitivity to Colistin or polymyxin B and in patients with myasthenia gravis. [17],[18] Colistin should be used with extreme caution in patients with porphyria.

 Resistance



Colistin has been shown to be active (even) in the presence of extended spectrum β-lactamases and metallo-β-lactamases. [1] Still, relatively high Colistin resistance rates in GNB (such as Acinetobacter spp., P. aeruginosa strains, and Enterobacteriaceae produced carbapenemases) have been recently reported worldwide. [1] Although the mechanisms of Colistin resistance have not been completely understood, alteration of the outer membrane of the (bacterial) cell, the reduction in cell envelope Mg 2+ and Ca 2+ contents and efflux pumps or production of enzyme(s) could be possible mechanisms. [1],[4],[26] The emergence of MDR or pandrug-resistant Gram-negative isolates, and especially, the emergence of Colistin resistance, are of concern. [1],[27] Colistin-resistant K. pneumoniae, A. baumannii, and P. aeruginosa pathogens may be encountered in clinical practice. [1] Hence, Colistin should be used judiciously (as treatment options for Colistin-resistant GNB are very limited). [1],[28] In a recent study on the emergence of MDR A. baumanii in patients with complicated urinary tract infections (North India); out of the total 224 isolates studied, 3.5% of total and 16% of the carbapenem-resistant MDR strains were found to be resistant to both Colistin and Tigecycline. [29] The pathogenic Neisseria spp., M. catarrhalis, H. pylori, P. mirabilis, S. marcescens, Morganella morganii, Chromobacterium, and Brucella species are naturally resistant to Colistin. [5],[30],[31],[32],[33],[34] Also, isolates of Inquilinus, Pandoraea, and Burkholderia associated with cystic fibrosis are intrinsically resistant to Colistin. [5],[35],[36],[37],[38] In P. mirabilis, Burkholderia cepacia, and Chromobacterium violaceum, polymyxin resistance has been associated with the changes in the lipid A. [5],[34],[39]

 Clinical Uses



Oral and topical route

Colistin sulfate is used orally for bowel decontamination and topically (as a powder) for the treatment of skin infections. [1]

Intravenous or intramuscular route

CMS has been used to treat ventilator-associated pneumonia (VAP) and bacteremia caused by MDR bacteria, such as P. aeruginosa, K. pneumoniae and A. baumannii. [30],[40] Intramuscular route is avoided as it is very painful and local irritation at the site of injection may occur. [17],[18]

Inhalational route

Prophylactic use

Colistin has been administered for the eradication of pathogens from the respiratory tract in cystic fibrosis (CF) patients in combination with ciprofloxacin administered orally for at least 3 weeks (or, even better, for 3 months) or by means of inhaled tobramycin as monotherapy for 4 weeks or longer. The therapeutic results of this preventive strategy have been successful. [10],[41]

Therapeutic use

Recent data in (critically ill) patients receiving Colistin by nebulization for management of pneumonia/VAP due to MDR GNB show favorable results. [10] High drug concentrations are usually achieved in sputum and bronchial secretions, maintained for 8-12 hours in the majority of patients. [16] However, further controlled trials are required in this regards. [1]

Intraventricular or intrathecal route

Colistin is usually administered intravenously, although adequate concentrations may not be achieved in the cerebrospinal fluid due to poor penetration of Colistin across the blood-brain barrier. [1],[3] Hence, Colistin can also be administered by the intraventricular or intrathecal route (considered if the ventriculitis is refractory to systemic antimicrobial therapy). [1],[3] Direct instillation of Colistin into the central nervous system (CNS) may cause chemical meningitis or ventriculitis. [1] Toxicity (probably or possibly) related to the topical administration of Colistin is seen in about 15% of patients. [1],[42] Administration of Colistin directly into the CNS appears to be successful and well tolerated. [1] Intra-ventricular and intrathecal administration of Colistin is an effective (and safe) option for treatment of post-neurosurgical meningitis (or ventriculitis) due to MDR GNB (especially when the intravenous route is not feasible/available). [1]

Combination therapy

Colistin can be used as combination therapy to improve its antibacterial activity. [5] A synergistic effect has been reported in different studies as regards the combination of Colistin with other antibiotics. [5],[40],[43],[44] Combination therapy with rifampicin and polymixin is one of the alternatives for treatment of MDR-GNB infections. [5],[45],[46],[47],[48],[49] Synergistic effect was detected in most of the studies that examined the combination of Colistin and rifampicin, whereas carbapenems exhibited a synergistic effect in a few studies. [5],[43] Sulbactam may be considered an option in association with Colistin, in the treatment of MDR A. baumannii infections. [5],[50],[51] Combinations of Colistin/Meropenem, Colistin/Rifampicin, and Colistin/Minocycline are synergistic in vitro against extensive drug-resistant A. baumannii. [5],[52] Wareham et al., have documented a synergistic effect of Colistin in combination with teicoplanin against MDR A. baumannii strains. [53] Glycopeptides have also shown synergy with polymyxin. [5],[44],[54]

 Colistin-uses in Children



Colistin is permitted for use in all children including infants. [55] Few efficacy data from controlled trials of its systemic use in infants and children are available because of the relative non-use of Colistin during the past 30 years. [55] Data on pharmacokinetic properties, drug behavior and dosing in children are also inadequate. [55] Published reports on the use of Colistin in children describe its use in case-series/case reports. Most published clinical data in children describes Colistin use in patients with cystic fibrosis. [55] Falagas et al., (2009) reviewed the literature on the systemic use of Colistin in children without cystic fibrosis. [56] Included in this review were 326 children from 10 case series and 15 case reports, of which only 17 children were evaluated in reports published after 1977. [56] Of these children, 271 were evaluable for clinical outcome-more than 90% were cured of infection or improved. [56] Nephrotoxicity occurred in 2.8% and no neurotoxicity was reported. Indications for use of colistin included sepsis, meningitis, pneumonia, and pyelonephritis. [56] [Table 3] [57],[58],[59],[60],[61],[62],[63] gives a summary of the recent case series and studies on systemic (intravenous) use of Colistin in pediatric population in the last 3 years (2009-2012) and includes only one Indian study (hence more data is required on the efficacy and safety of Colistin in Indian children). [59] Recent case series on the use of inhaled Colistin for the treatment of VAP and tracheobronchitis due to MDR A. baumanii and P. aeruginosa in critically-ill pediatric patients and neonates, have found Colistin treatment to be effective, safe, and tolerable without any adverse effects. [64],[65],[66]{Table 3}

In conclusion, recent studies and case reports have found Colistin to be safe and effective in the treatment of critically ill children with MDR GNB infections (more studies are required for confirming these findings). [57],[58],[59],[60],[61],[62],[63],[64],[65],[66]

 Acknowledgment



The authors thank Dr. Sandhya Kamath, Dean of Seth G. S. Medical College and K. E. M. Hospital for granting permission to publish this manuscript.

References

1Michalopoulos AS, Karatza DC. Multidrug-resistant gram-negative infections: The use of colistin. Expert Rev Anti Infect Ther 2010;8:1009-17.
2Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.
3Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
4Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: Similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007;5:811-21.
5Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: An update on the antibiotic of the 21 st century. Expert Rev Anti Infect Ther 2012;10:917-34.
6Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-8.
7Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: What are the treatment options? Drugs 2009;69:1879-901.
8Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 2011;11:464-9.
9Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1964;23:552-74.
10Michalopoulos A, Papadakis E. Inhaled anti-infective agents: Emphasis on colistin. Infection 2010;38:81-8.
11Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84.
12CIMS India. © 2012 UBM Medica. Available from: www.mims.com/India/drug/info/colistin%20sulfate?type=full [Last cited on 2013 Jan 5].
13Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
14Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: A review of the recent literature. Clin Med Res 2006;4:138-46.
15Curitis JR, Eastwood JB. Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis. Br Med J 1968;1:484-5.
16Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008;24:377-91.
17Xylistin package insert information (updated Sept 2011). Xylistin 10,00,000 IU vial-Colistimethate Sodium BP. Cipla pharmaceuticals, India; 2011.
18Colinem package insert information. Colinem 1 million IU vial-Colistimethate Sodium BP. Macleods Pharmaceuticals Ltd, Mumbai, India.
19Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: A retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194-9.
20Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-21.
21Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methane sulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6.
22Michalopoulos AS, Falagas ME. Colistin: Recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011;1:30.
23Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51.
24Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1:14.
25Papagelopoulos PJ, Mavrogenis AF, Giannitsioti E, Kikilas A, Kanellakopoulou K, Soucacos PN. Management of a multidrug-resistant Pseudomonas aeruginosa infected total knee arthroplasty using colistin. A case report and review of the literature. J Arthroplasty 2007;22:457-63.
26Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999;33:960-7.
27Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84.
28Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case-control study. Crit Care Med 2008;36:807-11.
29Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline and colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in North India. Indian J Med Res 2011;133:681-4.
30Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008;21:449-65.
31Doern GV, Morse SA. Branhamella (Neisseria) catarrhalis: Criteria for laboratory identification. J Clin Microbiol 1980;11:193-5.
32Glupczynski Y, Delmee M, Bruck C, Labbe M, Avesani V, Burette A. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents. Eur J Epidemiol 1988;4:154-7.
33García-Rodríguez JA, García-García MI, García-Sánchez E, García-Sánchez JE, Muñoz Bellido JL. In vitro activity of 16 antimicrobial agents against Helicobacter (Campylobacter) pylori. Enferm Infecc Microbiol Clin 1989;7:544-6.
34Sidorczyk Z, Zähringer U, Rietschel ET. Chemical structure of the lipid A component of the lipopolysaccharide from a Proteus mirabilis re-mutant. Eur J Biochem 1983;137:15-22.
35Schmoldt S, Latzin P, Heesemann J, Griese M, Imhof A, Hogardt M. Clonal analysis of Inquilinus limosus isolates from six cystic fibrosis patients and specific serum antibody response. J Med Microbiol 2006;55:1425-33.
36Daneshvar MI, Hollis DG, Steigerwalt AG, Whitney AM, Spangler L, Douglas MP, et al. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J Clin Microbiol 2001;39:1819-26.
37Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57-80.
38Alonso A, Martínez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997;41:1140-2.
39Hase S, Reitschel ET. The chemical structure of the lipid A component of lipopolysaccharides from Chromobacterium violaceum NCTC 9694. Eur J Biochem 1977;75:23-34.
40Nation RL, Li J. Colistin in the 21 st century. Curr Opin Infect Dis 2009;22:535-43.
41Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005;4:49-54.
42Cascio A, Conti A, Sinardi L, Iaria C, Angileri FF, Stassi G, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis 2010;14:e572-9.
43Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008;14:816-27.
44Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:5316-22.
45Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001;40:117-20.
46Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003;15:235-8.
47Hogg GM, Barr JG, Webb CH. In vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998;41:494-5.
48Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant acinetobacter baumannii. J Infect 2006;53:274-8.
49Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-20.
50Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: Clinical impact and therapeutic options. Int J Antimicrob Agents 2012;39:105-14.
51Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2012;39:180-1.
52Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis 2011;11:109.
53Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011;66:1047-51.
54Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010;48:3558-62.
55Bell EA. Colistin: Its role in pediatrics. [pharmacology consult] Infectious diseases in children. July 2012. [p-18.Healio.com/Pediatrics]. Available from: http://www.healio.com/Pediatrics/Vaccine-Preventable%20Diseases/News [Last accessed on 2013 Jan 8].
56Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: A systematic review of the literature. Int J Antimicrob Agents 2009;33:503.e1-503.e13.
57Tamma PD, Newland JG, Pannaraj PS, Metjian TA, Banerjee R, Gerber JS, et al. The use of intravenous colistin among children in the united states: Results from a multicenter, case series. Pediatr Infect Dis J 2013;32:17-22.
58Paksu MS, Paksu S, Karadag A, Sensoy G, Asilioglu N, Yildizdas D, et al. Old agent, new experience: Colistin use in the paediatric Intensive Care Unit: A multicentre study. Int J Antimicrob Agents 2012;40:140-4.
59Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V. Intravenous colistin administration in Neonates. Pediatr Infect Dis J 2011;30:218-21.
60Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V, et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010;169:867-74.
61Celebi S, Hacimustafaoglu M, Koksal N, Ozkan H, Çetinkaya M. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. Pediatr Int 2010;52:410-4.
62Rosanova M, Epelbaum C, Noman A, Villasboas M, Alvarez V, Berberian G, et al. Use of colistin in a pediatric burn unit in Argentina. J Burn Care Res 2009;30:612-5.
63Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009;28:123-7.
64Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, et al. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: A preliminary report. Pediatr Pulmonol 2011;46:60-6.
65Falagas ME, Sideri G, Korbila IP, Vouloumanou EK, Papadatos JH, Kafetzis DA. Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol 2010;45:1135-40.
66Celik IH, Oguz SS, Demirel G, Erdeve O, Dilmen U. Outcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: A retrospective chart review. Eur J Pediatr 2012;171:311-6.

 
Wednesday, February 19, 2020
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer